{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:34:30Z","timestamp":1784302470828,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["3T32DK007061-48S1"],"award-info":[{"award-number":["3T32DK007061-48S1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The immune system of healthy individuals is capable of regulating autoimmunity through multiple mechanisms. In Type 1 Diabetes (T1D) we recently discovered natural IgM, although present at normal levels, is unable to perform its normal immunoregulatory function. Treating diabetic mice with IgM from healthy donors led to reversal of disease without immune depletion. To investigate the therapeutic potential of a human preparation of IgM, we administered an IgM-enriched preparation of immunoglobulin called Pentaglobin. Administration of Pentaglobin therapy reversed disease in diabetic NOD mice and boosted CD4\u2009+\u2009Foxp3\u2009+\u2009Tregs. Importantly, the impact of Pentaglobin on the immune system was limited to inhibiting beta cell destruction but was not immune depleting nor did it inhibit the immunization response to an irrelevant antigen. These findings indicate that inhibition of deleterious autoimmunity in T1D is possible while leaving protective immunity fully intact.<\/jats:p>","DOI":"10.1038\/s41598-022-15676-8","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T13:11:06Z","timestamp":1657631466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A human IgM enriched immunoglobulin preparation, Pentaglobin, reverses autoimmune diabetes without immune suppression in NOD mice"],"prefix":"10.1038","volume":"12","author":[{"given":"Christopher S.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilee M.","family":"Hoopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"15676_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.2337\/diabetes.54.7.2019","volume":"54","author":"DJ Moore","year":"2005","unstructured":"Moore, D. J., Noorchashm, H., Lin, T. H., Greeley, S. A. & Naji, A. NOD B-cells are insufficient to incite T-cell-mediated anti-islet autoimmunity. Diabetes 54, 2019\u20132025 (2005).","journal-title":"Diabetes"},{"key":"15676_CR2","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.4049\/jimmunol.167.8.4351","volume":"167","author":"SA Greeley","year":"2001","unstructured":"Greeley, S. A. et al. Impaired activation of islet-reactive CD4 T cells in pancreatic lymph nodes of B cell-deficient nonobese diabetic mice. J. Immunol. 167, 4351\u20134357 (2001).","journal-title":"J. Immunol."},{"key":"15676_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrcardio.2010.35","volume":"7","author":"A Brown","year":"2010","unstructured":"Brown, A., Reynolds, L. R. & Bruemmer, D. Intensive glycemic control and cardiovascular disease: an update. Nat. Rev. Cardiol. 7, 369\u2013375 (2010).","journal-title":"Nat. Rev. Cardiol."},{"key":"15676_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI83840DS1","volume":"126","author":"N Chamberlain","year":"2016","unstructured":"Chamberlain, N. et al. Rituximab does not reset defective early B cell tolerance checkpoints. J. Clin. Invest. 126, 1\u20136. https:\/\/doi.org\/10.1172\/JCI83840DS1 (2016).","journal-title":"J. Clin. Invest."},{"key":"15676_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2337\/dc13-0626","volume":"37","author":"MD Pescovitz","year":"2014","unstructured":"Pescovitz, M. D. et al. B-lymphocyte depletion with rituximab and \u03b2-cell function: two-year results. Diabetes Care 37, 453\u2013459. https:\/\/doi.org\/10.2337\/dc13-0626 (2014).","journal-title":"Diabetes Care"},{"key":"15676_CR6","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1056\/NEJMoa012864","volume":"346","author":"KC Herold","year":"2002","unstructured":"Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692\u20131698. https:\/\/doi.org\/10.1056\/NEJMoa012864 (2002).","journal-title":"N. Engl. J. Med."},{"key":"15676_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI81722DS1","volume":"125","author":"MR Rigby","year":"2015","unstructured":"Rigby, M. R. et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J. Clin. Investig. 125, 1\u201312. https:\/\/doi.org\/10.1172\/JCI81722DS1 (2015).","journal-title":"J. Clin. Investig."},{"key":"15676_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2337\/dc20-2260","volume":"44","author":"JM Gregory","year":"2021","unstructured":"Gregory, J. M. et al. COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic\u2019s impact in type 1 and type 2 diabetes. Diabetes Care 44, 526\u2013532. https:\/\/doi.org\/10.2337\/dc20-2260 (2021).","journal-title":"Diabetes Care"},{"key":"15676_CR9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.11.8133","author":"G Zekavat","year":"2008","unstructured":"Zekavat, G. et al. In vivo BLyS\/BAFF neutralization ameliorates islet-directed autoimmunity in non-obese diabetic (NOD) mice. J. Immunol. https:\/\/doi.org\/10.4049\/jimmunol.181.11.8133 (2008).","journal-title":"J. Immunol."},{"key":"15676_CR10","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.4049\/jimmunol.167.10.5535","volume":"167","author":"C Hulbert","year":"2001","unstructured":"Hulbert, C., Riseili, B., Rojas, M. & Thomas, J. W. Cutting edge: B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J. Immunol. 167, 5535\u20135538. https:\/\/doi.org\/10.4049\/jimmunol.167.10.5535 (2001).","journal-title":"J. Immunol."},{"key":"15676_CR11","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"RA Insel","year":"2015","unstructured":"Insel, R. A. et al. Staging presymptomatic type 1 diabetes: A scientific statement of jdrf, the endocrine society, and the American diabetes association. Diabetes Care 38, 1964\u20131974. https:\/\/doi.org\/10.2337\/dc15-1419 (2015).","journal-title":"Diabetes Care"},{"key":"15676_CR12","doi-asserted-by":"publisher","DOI":"10.2337\/db18-0456","author":"CS Wilson","year":"2018","unstructured":"Wilson, C. S. et al. Healthy donor polyclonal IgM\u2019s diminish B lymphocyte autoreactivity, enhance treg generation, and reverse T1D in NOD mice. Diabetes https:\/\/doi.org\/10.2337\/db18-0456 (2018).","journal-title":"Diabetes"},{"key":"15676_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2362.1993.tb00963.x","volume":"23","author":"SK Jackson","year":"1993","unstructured":"Jackson, S. K. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur. J. Clin. Invest. 23, 540\u2013545. https:\/\/doi.org\/10.1111\/j.1365-2362.1993.tb00963.x (1993).","journal-title":"Eur. J. Clin. Invest."},{"key":"15676_CR14","first-page":"219","volume":"7","author":"S Tu\u011frul","year":"2001","unstructured":"Tu\u011frul, S. et al. The effect of pentaglobin therapy on prognosis in patients with severe sepsis. Ulus. Travma Derg. 7, 219\u2013223 (2001).","journal-title":"Ulus. Travma Derg."},{"issue":"Suppl 1","key":"15676_CR15","first-page":"S93","volume":"14","author":"S Colagiuri","year":"1996","unstructured":"Colagiuri, S. et al. Intravenous immunoglobulin therapy for autoimmune diabetes mellitus. Clin. Exp. Rheumatol. 14(Suppl 1), S93\u2013S97 (1996).","journal-title":"Clin. Exp. Rheumatol."},{"key":"15676_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1365-2249.2007.03545.x","volume":"151","author":"A Gonzalez-Quintela","year":"2008","unstructured":"Gonzalez-Quintela, A. et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin. Exp. Immunol. 151, 42\u201350. https:\/\/doi.org\/10.1111\/j.1365-2249.2007.03545.x (2008).","journal-title":"Clin. Exp. Immunol."},{"key":"15676_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/eji.201141890","volume":"42","author":"YS Choi","year":"2012","unstructured":"Choi, Y. S., Dieter, J. A., Rothaeusler, K., Luo, Z. & Baumgarth, N. B-1 cells in the bone marrow are a significant source of natural IgM. Eur. J. Immunol. 42, 120\u2013129. https:\/\/doi.org\/10.1002\/eji.201141890 (2012).","journal-title":"Eur. J. Immunol."},{"key":"15676_CR18","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.4049\/jimmunol.1401880","volume":"194","author":"TTT Nguyen","year":"2015","unstructured":"Nguyen, T. T. T., Elsner, R. & Baumgarth, N. Natural IgM prevents autoimmunity by enforcing B cell central tolerance induction. J. Immunol. 194, 1489\u20131502. https:\/\/doi.org\/10.4049\/jimmunol.1401880 (2015).","journal-title":"J. Immunol."},{"key":"15676_CR19","doi-asserted-by":"publisher","first-page":"E2699","DOI":"10.1073\/pnas.1210706109","volume":"109","author":"R Ouchida","year":"2012","unstructured":"Ouchida, R. et al. Critical role of the IgM Fc receptor in IgM homeostasis, B-cell survival, and humoral immune responses. Proc. Natl. Acad. Sci. 109, E2699\u2013E2706. https:\/\/doi.org\/10.1073\/pnas.1210706109 (2012).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"15676_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/SLA.0b013e31826b4ba9","volume":"256","author":"P Chhabra","year":"2012","unstructured":"Chhabra, P., Schlegel, K., Okusa, M. D., Lobo, P. I. & Brayman, K. L. Naturally occurring immunoglobulin M (nIgM) autoantibodies prevent autoimmune diabetes and mitigate inflammation after transplantation. Ann. Surg. 256, 634\u2013641. https:\/\/doi.org\/10.1097\/SLA.0b013e31826b4ba9 (2012).","journal-title":"Ann. Surg."},{"key":"15676_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ni.3677","volume":"18","author":"TTT Nguyen","year":"2017","unstructured":"Nguyen, T. T. T. et al. The IgM receptor Fc\u03bcR limits tonic BCR signaling by regulating expression of the IgM BCR. Nat. Immunol. 18, 321\u2013333. https:\/\/doi.org\/10.1038\/ni.3677 (2017).","journal-title":"Nat. Immunol."},{"key":"15676_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4049\/jimmunol.1402025","volume":"194","author":"M Colucci","year":"2015","unstructured":"Colucci, M. et al. Sialylation of N-linked glycans influences the immunomodulatory effects of IgM on T cells. J. Immunol. 194, 151\u2013157. https:\/\/doi.org\/10.4049\/jimmunol.1402025 (2015).","journal-title":"J. Immunol."},{"key":"15676_CR23","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/art.34537","volume":"64","author":"J Vas","year":"2012","unstructured":"Vas, J., Gr\u00f6nwall, C., Marshak-Rothstein, A. & Silverman, G. J. Natural antibody to apoptotic cell membranes inhibits the proinflammatory properties of lupus autoantibody immune complexes. Arthritis Rheum. 64, 3388\u20133398. https:\/\/doi.org\/10.1002\/art.34537 (2012).","journal-title":"Arthritis Rheum."},{"key":"15676_CR24","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.4049\/jimmunol.1101762","volume":"188","author":"PI Lobo","year":"2012","unstructured":"Lobo, P. I. et al. Natural IgM anti-leukocyte autoantibodies attenuate excess inflammation mediated by innate and adaptive immune mechanisms involving Th-17. J. Immunol. 188, 1675\u20131685. https:\/\/doi.org\/10.4049\/jimmunol.1101762 (2012).","journal-title":"J. Immunol."},{"key":"15676_CR25","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.4049\/jimmunol.0902640","volume":"184","author":"C Notley","year":"2010","unstructured":"Notley, C., Baker, N. & Ehrenstein, M. R. Secreted IgM enhances B cell receptor signaling and promotes splenic but impairs peritoneal B cell survival. J. Immunol. 184, 3386\u20133393. https:\/\/doi.org\/10.4049\/jimmunol.0902640 (2010).","journal-title":"J. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15676-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15676-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15676-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:56:04Z","timestamp":1669359364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15676-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["15676"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-15676-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11731"}}